Previous 10 | Next 10 |
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, reported today that updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen ® ...
Initiating Coverage of LCTX Lineage Cell Therapeutics is developing cellular-based therapies for use as standardized, “off-the-shelf” products to restore tissue damaged by disease processes. The company has developed a proprietary technology for growing early cells into mature ce...
Image source: The Motley Fool. Lineage Cell Therapeutics, Inc. (NYSEMKT: LCTX) Q2 2021 Earnings Call Aug 12, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Lineage Cell Therapeutics, Inc. (LCTX) Q2 2021 Earnings Ca...
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Ioana Hone – Director of Investor Relations Brian Culley – Chief Executive Officer Kevin Cook – Chief Financial Officer Conference Call Participants Kri...
Lineage Cell Therapeutics (NYSE:LCTX): Q2 GAAP EPS of -$0.03 beats by $0.01. Revenue of $0.51M (+30.8% Y/Y) misses by $0.21M. Press Release Cash, cash equivalents and marketable securities totaled $68.7 million as of June 30, 2021. For further details see: Lineage Cell Therapeutics EPS ...
OpRegen ® Continued to Demonstrate Functional and Anatomical Improvements in Patients with Dry AMD Three Cases of Retinal Tissue Restoration Reported; Longest of Which Has Lasted 3 Years Company Added to Russell 3000 ® and Russell Microcap ® ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be participating in and prese...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2021 financial and operating results on Thursday, August 12, 20...
Eighty-Three Percent of All Cohort 4 Patients Continued to Exhibit Stable or Improved BCVA At Least 6 Months Post-Treatment; Visual Acuity Declined in the Majority of Untreated Eyes Three Patients with Evidence of Retinal Tissue Restoration Continue to Demonstrate Areas of R...
Multidrug resistance is a growing opportunity for investors interested in biotech. The modern world has been experiencing a dramatic decrease in the effectiveness of antimicrobial agents on bacterial pathogens. This is an emerging health problem according to the U.S. Center for Disease Control...
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...